Elephas Names Mike Szulczewski Executive Vice President, Technology
Madison, WI, March 22, 2021 -- Elephas Biosciences Corporation (Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today Mike Szulczewski has joined the company as Executive Vice President, Technology.
Szulczewski is a long-time executive with broad experience architecting and managing the development of novel instruments within the field of laser microscopy. He will primarily be responsible for scaling the engineering efforts of the company.
"We are excited to announce another key addition to the leadership team," said Maneesh Arora, founder and CEO of Elephas. "Mike’s experience and impact within the fields of imaging and microscopy will be an integral asset as we continue to build the platform.”
Szulczewski started his career as an engineer and sales manager for several instrument companies before founding Prairie-Technologies in 1995. During the 18 years Szulczewski acted as President, Prairie-Technologies introduced a number of innovative microscopes that have since become commonplace within research labs across the globe. Eventually, Prairie-Technologies was acquired by Bruker, where Szulczewski served as Chief Technology Officer prior to joining Elephas.
"I’m very excited to lead an engineering team to build the imaging platform that will help create personalized treatment options and improve cancer care”, said Szulczewski.
Szulczewski earned his bachelor’s degree in electrical engineering from the University of Wisconsin – Madison.
Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. We plan to use the power of our platform to deliver a global solution that can revolutionize cancer treatment for every individual. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
CGLife on Behalf of Elephas